Navigation Links
Isis Pharmaceuticals to Present at The Wells Fargo 2010 Healthcare Conference
Date:6/16/2010

CARLSBAD, Calif., June 16 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Wells Fargo's 2010 Healthcare Conference on Wednesday, June 23, 2010 at 2:00 p.m. ET at the InterContinental Boston.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 22 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide.  Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Obamas Healthcare Reform Bill and its Impact on the U.S. Healthcare Markets (Pharmaceuticals, Medical Devices and Health Insurance)
2. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
3. Syndax Pharmaceuticals Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
4. Jiangbo Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Global Market
5. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
6. Alexza Pharmaceuticals to Present at Jefferies 2010 Global Life Sciences Conference
7. Hospira Announces Further Extension of Tender Offer for Shares of Javelin Pharmaceuticals
8. Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd.
9. Jazz Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
10. Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development
11. Shire Receives LIALDA(R) Paragraph IV Notice Letter From Zydus Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... -- In 2016, Embodied Labs took top prize ... came away with $25,000 in seed-fund investment. Embodied Labs ... "entering the life of another" and by the Journal ... medical professionals in an entirely new dimension." Building upon ... for the Department of Education,s EdSimChallenge, where they received ...
(Date:6/10/2017)... Burchfield, DPM, is recognized by Continental Who,s Who as a Pinnacle ... Alabama . Dr. Burchfield serves as a ... 20 years of experience, as well as expertise in the areas ... "The podiatry professional   ... welcome you to his practice," the company,s website states. "We want ...
(Date:6/8/2017)... 8, 2017   Responding to Heath Ledger,s ... death of singer Chris Cornell in May, the ... offers a free online psychiatric drug side ... families about psychotropic drug risks. The father ... from an accidental overdose, has called for tighter rules on ...
Breaking Medicine Technology:
(Date:6/28/2017)... , ... June 28, 2017 , ... ... County and the surrounding regions access to insurance assistance and financial planning services, ... 25: Ministries to assist families in the region facing financial crisis. , Matthew ...
(Date:6/27/2017)... ... June 27, 2017 , ... DrugDev understands that for many ... trust the sponsor to pay them correctly and on time. As the search for ... strategies that encourage sites to work on their studies. , At a complimentary live ...
(Date:6/27/2017)... Syracuse, NY (PRWEB) , ... June 27, 2017 , ... ... EarQ members. The three-day event was held in Syracuse, New York, where EarQ is ... a changing industry, how to connect with today’s savvy consumer, and the latest ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... the expansion of Atmosera Managed Azure Services . The trusted, transparent, and ... support of the company’s growing customer base. Atmosera’s next generation services include integrated ...
(Date:6/27/2017)... Hollywood, CA (PRWEB) , ... June 27, 2017 ... ... orthodontic treatments . Orthodontics is a dental specialty that focuses on treating ... appliances. Benefits include improved aesthetics and function. , North Hollywood dentist ...
Breaking Medicine News(10 mins):